Literature DB >> 25690144

[Burden of influenza virus type B and mismatch with the flu vaccine in Spain].

Jose Ma Eiros-Bouza1, Alberto Pérez-Rubio.   

Abstract

INTRODUCTION: Since the 80s two lineages of type B viruses are co - circulating in the world. Antigenic differences between them are important and it leads to lack of cross-reactivity. The impact on the burden of disease due to influenza B virus, poor foresight in estimating which of the two lineages of B viruses circulate in the season, and the consequent lack of immunity in case of including the wrong strain make that the availability of the quadrivalent vaccine is very useful. The aim of this paper is to analyze the past influenza seasons in Spain to assess the burden of disease, divergence between the vaccine strain and the circulating B and viral characteristics associated with type B in each seasonal epidemic.
MATERIAL AND METHODS: Review of all reports issued by the Influenza Surveillance System in Spain since the 2003-2004 season to 2012-2013.
RESULTS: Over the past influenza seasons, although type A was present mostly, circulation of influenza B virus in each season was observed, even being co - dominant in some of them. In a high number of seasons the divergence between the vaccine strain and the circulating strain lineage has been observed
CONCLUSIONS: The protective effect of influenza vaccine has varied depending on the type / subtype of influenza virus studied. The vaccine effectiveness against influenza infection by influenza B virus has varied greatly depending on the season analyzed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25690144

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  9 in total

1.  Cell culture-derived flu vaccine: Present and future.

Authors:  Alberto Pérez Rubio; Jose María Eiros
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

2.  Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.

Authors:  Alberto Pérez-Rubio; Julio Ancochea; Jose María Eiros Bouza
Journal:  Hum Vaccin Immunother       Date:  2020-04-07       Impact factor: 3.452

3.  Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.

Authors:  Stephan Bart; Kevin Cannon; Darrell Herrington; Richard Mills; Eduardo Forleo-Neto; Kelly Lindert; Ahmed Abdul Mateen
Journal:  Hum Vaccin Immunother       Date:  2016-06-20       Impact factor: 3.452

Review 4.  Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.

Authors:  Edward W Thommes; Morgan Kruse; Michele Kohli; Rohita Sharma; Stephen G Noorduyn
Journal:  Hum Vaccin Immunother       Date:  2016-11-18       Impact factor: 3.452

5.  [Description of Influenza B in seasonal epidemics in Spain].

Authors:  R Ortiz de Lejarazu; J Díez Domingo; A Gil de Miguel; F Martinón Torres; C Guzmán Quilo; J M Guillén; B Piedrafita; E Redondo Marguello
Journal:  Rev Esp Quimioter       Date:  2018-11-05       Impact factor: 1.553

6.  Knowledge and Attitudes about the Flu Vaccine among Pregnant Women in the Valencian Community (Spain).

Authors:  Noelia Rodríguez-Blanco; José Tuells
Journal:  Medicina (Kaunas)       Date:  2019-08-11       Impact factor: 2.430

7.  From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.

Authors:  Pascal Crépey; Esther Redondo; Javier Díez-Domingo; Raúl Ortiz de Lejarazu; Federico Martinón-Torres; Ángel Gil de Miguel; Juan Luis López-Belmonte; Fabián P Alvarez; Hélène Bricout; Míriam Solozabal
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

8.  Real-time surveillance systems: Applicability for the control of influenza in acute care.

Authors:  Víctor Quirós-González; Paz Rodríguez-Pérez; Ana Mª Haro-Pérez; Mª Mar Jiménez-Rodríguez; José Ángel Maderuelo-Fernández; José Mª Eiros
Journal:  Influenza Other Respir Viruses       Date:  2020-03-02       Impact factor: 4.380

9.  [Description of Influenza B in seasonal epidemic in Cantabria during the beginning of the pandemia due to SARS-CoV-2].

Authors:  D Pablo-Marcos; A Rodríguez-Fernández; M Gozalo; J Agüero; F Arnaiz de Las Revillas; J Calvo
Journal:  Rev Esp Quimioter       Date:  2020-09-22       Impact factor: 1.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.